Bicocca Open Archive

Logo unimib boa
STRAZZABOSCO, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 30.727
AS - Asia 15.140
EU - Europa 11.295
SA - Sud America 2.081
AF - Africa 335
OC - Oceania 37
Continente sconosciuto - Info sul continente non disponibili 34
Totale 59.649
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 28.748
SG - Singapore 5.337
CN - Cina 3.433
HK - Hong Kong 2.135
VN - Vietnam 1.984
RU - Federazione Russa 1.930
CA - Canada 1.806
IT - Italia 1.756
SE - Svezia 1.635
BR - Brasile 1.558
DE - Germania 1.351
IE - Irlanda 1.251
UA - Ucraina 1.151
GB - Regno Unito 676
FR - Francia 473
IN - India 443
FI - Finlandia 381
KR - Corea 317
BD - Bangladesh 307
AR - Argentina 202
TR - Turchia 190
IQ - Iraq 181
AT - Austria 121
ZA - Sudafrica 118
NL - Olanda 110
DK - Danimarca 106
MX - Messico 105
PK - Pakistan 105
ID - Indonesia 104
JP - Giappone 100
SA - Arabia Saudita 80
ES - Italia 79
EC - Ecuador 76
CO - Colombia 70
PH - Filippine 65
PL - Polonia 58
UZ - Uzbekistan 56
VE - Venezuela 56
MA - Marocco 51
BE - Belgio 46
CL - Cile 42
KE - Kenya 30
MY - Malesia 29
JO - Giordania 28
PY - Paraguay 28
BG - Bulgaria 27
EU - Europa 27
AU - Australia 26
CZ - Repubblica Ceca 26
TW - Taiwan 26
IR - Iran 23
TN - Tunisia 23
AE - Emirati Arabi Uniti 22
NP - Nepal 22
ET - Etiopia 21
JM - Giamaica 20
DZ - Algeria 19
EG - Egitto 19
PE - Perù 19
AZ - Azerbaigian 18
RO - Romania 17
UY - Uruguay 17
CH - Svizzera 16
OM - Oman 16
LT - Lituania 15
IL - Israele 14
PS - Palestinian Territory 14
TH - Thailandia 14
KZ - Kazakistan 13
BO - Bolivia 10
SN - Senegal 10
NZ - Nuova Zelanda 9
CR - Costa Rica 8
DO - Repubblica Dominicana 8
LB - Libano 8
MD - Moldavia 8
NO - Norvegia 8
RS - Serbia 8
BH - Bahrain 7
BY - Bielorussia 7
HU - Ungheria 7
KG - Kirghizistan 7
KW - Kuwait 7
PT - Portogallo 7
TT - Trinidad e Tobago 7
GA - Gabon 6
GT - Guatemala 6
HN - Honduras 6
MN - Mongolia 6
AL - Albania 5
GE - Georgia 5
GR - Grecia 5
MM - Myanmar 5
NI - Nicaragua 5
SC - Seychelles 5
SY - Repubblica araba siriana 5
A2 - ???statistics.table.value.countryCode.A2??? 4
PA - Panama 4
AM - Armenia 3
AO - Angola 3
Totale 59.581
Salva come PNG Salva come JPEG
Città #
Ann Arbor 3.259
Singapore 3.037
Woodbridge 2.789
Ashburn 2.608
Fairfield 2.114
Hong Kong 2.094
Houston 1.916
Toronto 1.413
Chandler 1.335
San Jose 1.249
Jacksonville 1.217
Dublin 1.214
Wilmington 1.002
Seattle 882
Frankfurt am Main 852
Cambridge 769
New York 717
Ho Chi Minh City 581
Dearborn 557
Princeton 534
Beijing 471
Santa Clara 465
Hanoi 452
Hefei 435
The Dalles 433
Chicago 429
Milan 419
Los Angeles 354
Dallas 353
Nanjing 293
Seoul 291
Lauterbourg 249
Lawrence 228
Council Bluffs 222
Altamura 204
Lachine 197
Shanghai 194
Buffalo 160
Boardman 151
Helsinki 146
São Paulo 137
Moscow 134
San Diego 129
Guangzhou 114
Rome 92
Vienna 89
Shenyang 88
Da Nang 86
Orem 86
Andover 76
Nanchang 76
Baghdad 75
Changsha 71
Tokyo 67
London 65
Ottawa 64
Hebei 63
Haiphong 62
Falls Church 57
Rio de Janeiro 57
Tianjin 57
Hangzhou 56
Philadelphia 56
Montreal 52
Columbus 50
Jiaxing 50
Johannesburg 49
Norwalk 49
Brooklyn 47
Dong Ket 47
Munich 47
Chennai 46
Fremont 45
Jakarta 45
Mountain View 45
Jinan 44
Tashkent 42
Boston 41
Nuremberg 41
Salt Lake City 41
Warsaw 41
Dhaka 40
Washington 38
Zhengzhou 38
Brasília 36
Brussels 36
Huizen 36
Pune 36
Denver 35
Hải Dương 35
Kunming 35
Belo Horizonte 33
Elk Grove Village 32
Phoenix 32
Can Tho 31
Mexico City 30
San Francisco 30
Lissone 29
Manchester 29
Redmond 29
Totale 39.604
Salva come PNG Salva come JPEG
Nome #
Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma 673
Impact of multidisciplinary team approach to liver tumors: 5-Years experience 522
Impact of multidisciplinary team approach to liver tumors in a tertiary center: 5-years experience 492
Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology 452
JNK SIGNALING ACTIVATED BY PLATELET-DERIVED GROWTH FACTOR D (PDGF-D) STIMULATES SECRETION OF VASCULAR ENDOTHELIAL GROWTH FACTOR-C (VEGF-C) BY CANCER-ASSOCIATED FIBROBLASTS TO PROMOTE LYMPHANGIOGENESIS AND EARLY METASTATIZATION IN CHOLANGIOCARCINOMA 429
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 388
Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma 386
Resveratrol impairs glioma stem cells proliferation and motility by modulating the wnt signaling pathway 385
Value-based outcome indicators in the management of hepatocellular carcinoma: Clinical test in a large multicenter study (VBMH study) 359
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 341
Health related quality of life in chronic liver diseases 325
Diagnostic value of dynamic contrast-enhanced CT with perfusion imaging in the quantitative assessment of tumor response to sorafenib in patients with advanced hepatocellular carcinoma: A feasibility study 323
Long term outcome of acute pancreatitis in Italy: Results of a multicentre study 321
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 318
Trattamento con Sofosbuvir e Ribavirina nei pazienti hcv-positivi listati per il trapianto di fegato: un analisi di costo-efficacia 317
Generation and performance of value-based outcome indicators in liver disease: The multicenter V.B.M.H. study 317
Dynamic contrast enhanced perfusion CT imaging: A diagnostic biomarker tool for survival prediction of tumour response to antiangiogenetic treatment in patients with advanced HCC lesions 317
Outcome indicators in liver cirrhosis: Application of value-based medicine in a large multicenter study (VBMH study) 313
Valproic Acid Inhibits Proliferation and Reduces Invasiveness in Glioma Stem Cells Through Wnt/β Catenin Signalling Activation 310
HCC persistence or recurrence after bridging therapy helps predict transplant list dropout and generate a more equitable exception policy 306
P1169 : Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 304
Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 301
Outcome Indicators in Primary Sclerosing Cholangitis: Interim Analysis Of The Value-Based Medicine In Hepatology (VBMH) Study 300
Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice 298
The impact of liver disease on the health-related quality of life 295
Effect of Silibinin on biliary lipid composition. Experimental and clinical study 292
A Comparison Between The Health-Related Quality Of Life Reported By The General Population And By Patients With Major Liver Diseases 288
Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis 288
Low-dose paclitaxel reduces S100A4 nuclear import to inhibit invasion and hematogenous metastasis of cholangiocarcinoma 287
Pathophysiologic implications of innate immunity and autoinflammation in the biliary epithelium 287
Value-based outcome indicators in liver cirrhosis: validation in a large multicenter study (VBMH study) 286
P0811 : Sofosbuvir-based direct-acting antivirals treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 286
Measurement of clinical outcomes and quality of life indicators as a new value-based approach to liver cirrhosis management 285
Subcutaneous insulin infusion (CSII) in italy: The third national survey [La terapia insulinica sottocutanea continua (CSII) in Italia. Terza indagine nazionale] 283
Characteristics of patients with Chronic Hepatitis C who have failed past treatment or who have never been treated: How much room left for Interferon? 282
Pathway-based analysis of primary biliary cirrhosis genome-wide association studies 280
Cholangiocyte biology as relevant to cystic liver diseases 278
Generation and Performance of Outcome Indicators in Liver Cirrhosis: The Value Based Medicine in Hepatology Study (V.B.M.H.) 278
Impatto dei farmaci anti virali ad azione diretta sulla cura dei pazienti con epatite C: un approccio di value-based medicine 276
The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities 275
Notch signaling regulates tubular morphogenesis during repair from biliary damage in mice 274
The Impact of Type of Liver Conditions on the Patients’ Health Related Quality of Life 271
A value-based approach to the management of patients with liver cirrhosis through the systematic measurement of clinical outcome and quality of life indicators 271
The cystic fibrosis transmembrane conductance regulator controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity 270
Tumor reactive stroma in cholangiocarcinoma: The fuel behind cancer aggressiveness 270
Ursodeoxycholic acid stimulates cholangiocyte fluid secretion in mice via CFTR-dependent ATP secretion. 267
Health Related Quality of Life in the Major Liver Conditions 267
Epithelial expression of angiogenic growth factors modulate arterial vasculogenesis in human liver development 265
Liver-allocation policies for patients affected by HCC in Europe 265
Value-based approach to hepatocellular carcinoma: outcome indicators tested in a large multicenter study (VBMH study) 264
ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice 263
Models of The Impact of Major Liver Diseases on Eq-5d Visual Analogue Scale and Utility-Index: Convergences and Divergences 263
Difference in health related quality of life of chronic liver diseases and general population 261
Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the " Cholangiocarcinoma" committee of the Italian Association for the Study of Liver disease 260
Epithelial-to-Mesenchymal Transition and Cancer Invasiveness: What Can We Learn from Cholangiocarcinoma? 260
The challenges of primary biliary cholangitis: What is new and what needs to be done 259
Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis 258
Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease. 256
Management of treatment-naïve chronic hepatitis C genotype 1 patients: A cost-effectiveness analysis of treatment options 256
Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching 255
The cholangiopathies: disorders of biliary epithelia 254
Sofosbuvir-based all-oral treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 254
Functional anatomy of normal bile ducts 253
Continuous subcutaneous insulin infusion in Italy: Third national survey 253
Foxa1 and Foxa2 regulate bile duct development in mice 252
Procoagulant phenotype of virus-infected pericytes is associated with portal thrombosis and intrapulmonary vascular dilations in fatal COVID-19 251
PGI31 Health Care Indicators to Measure Quality of Care in Patients with Liver Diseases 251
Analysis of liver repair mechanisms in Alagille syndrome and biliary atresia reveals a role for notch signaling 250
Effect of age on single- and multiple-dose pharmacokinetics of erythromycin 250
Loss of CFTR affects biliary epithelium innate immunity and causes TLR4NF-κB-mediated inflammatory response in mice 250
pka-dependent p-ser- 675 β-catenin phosphorylation increases cholangiocyte motility in pkhd1del4/del4 mice, a model of fibropolycystic liver diseases caused by defective fibrocystin function 250
Revisiting Epithelial-to-Mesenchymal Transition in Liver Fibrosis: Clues for a Better Understanding of the "reactive" Biliary Epithelial Phenotype 249
Cholangiocyte pathobiology 249
Animal models of cholestasis: An update on inflammatory cholangiopathies 248
Effect of Silybin on biliary lipid composition in rats 247
"The city of Hepar": Rituals, gastronomy, and politics at the origins of the modern names for the liver 247
Should new antiviral treatments be considered in elderly Chronic Hepatitis C patients? 247
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways 247
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. 246
Intracellular alkalinization stimulates bile flow and vesicular-mediated exocytosis in IPRL 244
Molecular mechanisms driving cholangiocarcinoma invasiveness: an overview 244
JNK SIGNALING ACTIVATED BY PLATELET-DERIVED GROWTH FACTOR D (PDGF-D) STIMULATES SECRETION OF VASCULAR ENDOTHELIAL GROWTH FACTOR-C (VEGF-C) BY CANCER-ASSOCIATED FIBROBLASTS TO PROMOTE LYMPHANGIOGENESIS AND EARLY METASTASIZATION IN CHOLANGIOCARCINOMA 243
Pka-dependent p-ser-675-catenin phosphorylation increases cholangiocyte motility in a mouse model of fibropolycystic liver diseases 243
Β-Catenin-Mediated Cxcl1 and Cxcl10 Secretion by Fibrocystin-Defective Cholangiocytes Regulates Peribiliary Recruitment of Fibrocytes in Congenital Hepatic Fibrosis 242
Sorafenib paradoxically activates the raf/mek/erk signaling in mice with polycystic liver disease (pld) caused by conditional deletion of polycystin-2 242
Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice 241
Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib 241
Applicazione della value-based medicine nella valutazione della cura dei pazienti affetti da epatite. 240
Monocyte/macrophage peribiliary recruitment by pkhd1-defective cholangiocytes induces expression of avb6 integrin on biliary cysts via tgf-β1 and tnf-α in congenital hepatic fibrosis 238
Intracellular pH regulation in isolated rat bile duct epithelial cells 237
Should Sofosbuvir-Based All-Oral Treatment Be Considered In Elderly Chronic Hepatitis C Patients? 237
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 236
Notch signaling and progenitor/ductular reaction in steatohepatitis 234
Novel association of HLA-haplotypes with primary sclerosing cholangitis (PSC) in a southern European population 233
Purinergic regulation of acid/base transport in human and rat biliary epithelial cell lines. 233
Altered store operated calcium entry increases cAMP production and ERK1/2 phosphorylation in Polycystin-2 defective cholangiocytes 233
PGI36 Relationship Between Clinical Severity and Health Related Quality of Life in Chronic Liver Diseases 233
Notch signaling and new therapeutic options in liver disease 232
Effect of ursodeoxycholic acid on intracellular pH in a bile duct epithelium-like cell line 231
Vascular biology of the biliary epithelium 231
Totale 28.354
Salva come PNG Salva come JPEG
Categoria #
all - tutte 198.030
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 198.030
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021303 0 0 0 0 0 0 0 0 0 0 0 303
2021/20222.877 130 293 499 219 101 210 133 197 143 199 244 509
2022/20235.338 594 1.602 470 404 435 810 72 278 369 31 178 95
2023/20243.783 151 142 112 179 505 1.038 764 139 333 33 24 363
2024/20258.323 551 1.073 423 324 775 275 522 405 757 1.178 652 1.388
2025/202619.971 2.210 1.393 1.359 1.726 2.090 1.183 2.554 1.068 1.823 1.932 2.015 618
Totale 60.652